Editorial

A Brief Overview of COVID-19 Vaccines

Abstract

No Abstract

1. Cui J, Li F, Shi ZL (2019). Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol, 17:181-192.
2. Alturki SO, Alturki SO, Connors J, Cusimano G, Kutzler MA, Izmirly AM, Haddad EK (2020). The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Front Immunol, 11:1880.
3. Krammer F (2020). SARS-CoV-2 vaccines in development. Nature, 586:516-527.
4. Martin JE, Louder MK, Holman LA, et al (2008). A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine, 26:6338-43.
5. Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C (2008). SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res, 18:290-301.
6. Wajnberg A, Amanat F, Firpo A, et al (2020). SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. Medxriv, 2020.07.14.20151126.
7. Yu J, Tostanoski LH, Peter L, et al (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 369:806-811.
8. Su F, Patel GB, Hu S, Chen W (2016). Induction of mucosal immunity through systemic immunization: Phantom or reality? Hum Vaccin Immunother, 12:1070-9.
9. Wang H, Zhang Y, Huang B, et al (2020). Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell, 182:713-721.e9.
10. Zhang Y, Zeng G, Pan H, et al (2020). Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial.2020.07.31.20161216.
11. Jackson LA, Anderson EJ, Rouphael NG, et al (2020). An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. 383:1920-1931.
12. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC (2021). COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci, 25:1663-1669.
13. Callaway E. The unequal scramble for coronavirus vaccines — by the numbers: Nature 24 August 2020 [updated 27 August 2020. Available from: https://www.nature.com/articles/d41586-020-02450-x
14. Russo AG, Decarli A, Valsecchi MG (2021). Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study. Vaccine, 39:2517-2525.
15. Callaway E. Mix-and-match COVID vaccines trigger potent immune response: Nature 593, 491; 19 May 2021 [Available from: https://www.nature.com/articles/d41586-021-01359-3#ref-CR1
16. Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents: Pfizer; March 31, 2021 [Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal
17. Coronavirus (COVID-19) Vaccinations: Our World in Data; 2021 [updated Jun 19, 2021. Available from: https://ourworldindata.org/covid-vaccinations
18. Coronavirus (COVID-19) Vaccinations: COVID-19 vaccine doses administered: Our World in Data; [updated Jun 19, 2021. Available from: https://ourworldindata.org/covid-vaccinations?country=
19. Coronavirus (COVID-19) Vaccinations: Share of people vaccinated against COVID-19: Our World in Data; [updated Jun 19, 2021. Available from: https://ourworldindata.org/covid-vaccinations?country=IRN
20. Coronavirus (COVID-19) Vaccinations: COVID-19 vaccine doses administered per 100 people: Our World in Data; [updated Jun 19, 2021. Available from: https://ourworldindata.org/covid-vaccinations?country=IRN
21. Coronavirus (COVID-19) Vaccinations: Share of the population fully vaccinated against COVID-19: Our World in Data. [updated Jun 19, 2021. Available from: https://ourworldindata.org/covid-vaccinations?country=IRN
22. Iwasaki A, Omer SB (2020). Why and How Vaccines Work. Cell, 183:290-295.
23. Pat Bass. What Is an Inactivated Vaccine? : verywellhealth; May 21, 2021 [Available from: https://www.verywellhealth.com/what-is-an-inactivated-vaccine-201081
24. Jiskoot W, Kersten GFA, MastrobattistaE, Slütter B (2019). Vaccines. Pharmaceutical Biotechnology, 281–304.
25. Holman DH, Wang D, Woraratanadharm J, Dong JY (2009). Viral Vectors. Vaccines for Biodefense and Emerging and Neglected Diseases:77–91.
26. Dee K, Goldfarb DM, Haney J, et al (2021). Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-19 epidemiology. J Infect Dis, jiab147.
Files
IssueVol 50 No 7 (2021) QRcode
SectionEditorial
Published2021-07-01
DOI https://doi.org/10.18502/ijph.v50i7.6656

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Farhud DD, Zokaei S. A Brief Overview of COVID-19 Vaccines. Iran J Public Health. 50(7):i-vi.